首页 › 慢性淋巴细胞白血病 › 马萨诸塞州 › Boston
Boston MA 慢性淋巴细胞白血病临床试验
31项针对 慢性淋巴细胞白血病的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
招募中3 期
- Dana Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
招募中2 期
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- Tufts Medical Center, Boston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
招募中1/2 期
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Massachusetts General Hospital, Boston
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
招募中3 期
- Dana-Farber Cancer Institute, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
招募中4 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
招募中2 期
- Massachusetts General Hospital, Boston
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
招募中2 期
- Research Site, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
招募中1 期欢迎健康志愿者
- Brigham and Women's Hospital, Boston
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
招募中2 期
- Boston Medical Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
招募中观察性研究
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
招募中观察性研究
- Dana-Farber Cancer Institute, Boston
Understanding Chronic Lymphocytic Leukemia
招募中观察性研究
- Dana Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
招募中2 期欢迎健康志愿者
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- Beth Israel Deaconess Medical Center, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
招募中2 期
- Dana-Farber Cancer Institute /ID# 230061, Boston
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
招募中1/2 期
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
招募中1 期
- Dana-Farber Cancer Institute, Boston
其他城市的 慢性淋巴细胞白血病试验
- Columbus, OH29 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA21 项研究
- Rochester, MN19 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI14 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
- Nashville, TN13 项研究
Boston的其他研究
- 乳腺癌110 项研究
- 非小细胞肺癌89 项研究
- 癌症（所有类型）86 项研究
- 结直肠癌63 项研究
- 转移性癌症63 项研究
- 肺癌62 项研究
- 卵巢癌61 项研究
- 前列腺癌60 项研究
- 抑郁症51 项研究
- 子宫内膜癌50 项研究
- 急性髓系白血病45 项研究
- 胰腺癌44 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。